J&J divests Laminar Stroke Tech to Jaguar LAA
Jaguar LAA has completed the acquisition of Johnson & Johnson’s Laminar program assets in a transaction that highlights a significant pivot in the cardiovascular medical technology landscape. Announced on September 11, 2026, the deal involves the transfer of a differentiated left atrial appendage closure technology from the global healthcare giant to a newly formed, independent firm. While the specific financial…